Analytical Data
-
Gene name
VEGF110
-
简介
Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF110 Protein, Human (HEK293) is the recombinant human-derived VEGF110 protein, expressed by HEK293, with tag free.
- Application
-
Alternative Names
VEGF; VEGFA; L-VEGF; N-VEGF; VPF; MVCD1
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P15692-9
-
Expression Region
A27-R136
-
Protein Length
Partial
-
Molecular Weight
13 kDa & 17-23 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. Abnormal VEGF expression is implicated in various diseases, including cancer, diabetic retinopathy, and age-related macular degeneration. The VEGF110 recombinant protein, a specific isoform of VEGF, has garnered attention due to its unique properties that enhance endothelial cell proliferation and migration, making it a potential therapeutic target. Research into VEGF110 focuses on its structural characteristics, signaling pathways, and interactions with specific receptors, contributing to a deeper understanding of angiogenic mechanisms. Moreover, studies are exploring its potential utility in regenerative medicine, tissue engineering, and as an adjunct therapy for ischemic diseases. By elucidating the functional aspects of VEGF110, researchers aim to harness its angiogenic capabilities to develop innovative treatments that can effectively manage various pathologies linked to aberrant vessel growth and function. Overall, the investigation of VEGF110 not only provides insights into fundamental biological processes but also opens avenues for developing targeted therapies that utilize its pro-angiogenic properties.
